Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Cancer Research|June 3, 2004
An increase in the expression of ribonucleotide reductase large subunit 1 is associated with gemcitabine resistance in non-small cell lung cancer cell linesJennifer D Davidson, Liandong Ma, Michael Flagella, et al.
The Journal of Biological Chemistry|May 7, 2015
Inhibition of Nicotinamide Phosphoribosyltransferase (NAMPT), an Enzyme Essential for NAD+ Biosynthesis, Leads to Altered Carbohydrate Metabolism in Cancer CellsBo Tan, Sucai Dong, Robert L Shepard, et al.
Cancer Research|November 13, 2014
Akt1 and akt3 exert opposing roles in the regulation of vascular tumor growthThuy L Phung, Wa Du, Qi Xue, et al.
The Journal of Biological Chemistry|December 15, 2012
Pharmacological inhibition of nicotinamide phosphoribosyltransferase (NAMPT), an enzyme essential for NAD+ biosynthesis, in human cancer cells: metabolic basis and potential clinical implicationsBo Tan, Debra A Young, Zhao-Hai Lu, et al.
European Journal of Cancer (Oxford, England : 1990)|January 21, 2014
A phase I trial of LY2584702 tosylate, a p70 S6 kinase inhibitor, in patients with advanced solid tumoursAnthony Tolcher, Jonathan Goldman, Amita Patnaik, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|April 30, 2021
A Phase I Study of an IDO-1 Inhibitor (LY3381916) as Monotherapy and in Combination With an Anti-PD-L1 Antibody (LY3300054) in Patients With Advanced CancerNuria Kotecki, Perrine Vuagnat, Bert H O'Neil, et al.
Bioorganic & Medicinal Chemistry Letters|April 16, 2018
Discovery of chiral dihydropyridopyrimidinones as potent, selective and orally bioavailable inhibitors of AKTSaravanan Parthasarathy, Kenneth Henry, Huaxing Pei, et al.
Molecular Cancer Therapeutics|October 22, 2017
Discovery of a Highly Selective NAMPT Inhibitor That Demonstrates Robust Efficacy and Improved Retinal Toxicity with Nicotinic Acid CoadministrationGenshi Zhao, Colin F Green, Yu-Hua Hui, et al.
Cancer Research|August 17, 2005
The protein kinase Cbeta-selective inhibitor, Enzastaurin (LY317615.HCl), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenograftsJeremy R Graff, Ann M McNulty, Kimberly Ross Hanna, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 15, 2019
The Folate Pathway Inhibitor Pemetrexed Pleiotropically Enhances Effects of Cancer ImmunotherapyDavid A Schaer, Sandaruwan Geeganage, Nelusha Amaladas, et al.
Pageof 2